What is GPx?
GPx operates at the intersection of clinical care and patient-centric technology. The company is dedicated to improving the quality of life for individuals managing chronic conditions through a suite of predictive innovations designed for seamless integration into daily routines. By prioritizing ease of use for patients and actionable insights for clinicians, GPx addresses the systemic inefficiencies in long-term disease management. Its market position is defined by a commitment to evidence-based outcomes, aiming to bridge the gap between complex medical data and accessible, personalized care delivery models that empower both the provider and the patient.
How much funding has GPx raised?
GPx has raised a total of $3.3M across 1 funding round:
Angel/Seed
$3.3M
Angel/Seed (2022): $3.3M with participation from The D4V, Pete Moran, and Hiroaki Kitano
Key Investors in GPx
The D4V
D4V is a Japanese venture capital firm established in partnership with IDEO, focusing on unlocking the global potential of startups through design-led insights and strategic capital.
Pete Moran
An investor with a background in creating engaging, modern experiences, bringing a unique perspective on user-centric design and market engagement to the health-tech sector.
Hiroaki Kitano
An influential figure in the scientific and technological community, providing strategic guidance and backing to ventures focused on complex, data-driven health solutions.
What's next for GPx?
With this major enterprise-level funding, GPx is poised to scale its predictive health platform and expand its clinical footprint. The strategic allocation of this capital will likely focus on enhancing the underlying algorithmic capabilities of its diagnostic tools and broadening its reach within the healthcare ecosystem. As the firm transitions from its initial development phase toward broader market adoption, the focus will shift to establishing robust partnerships with healthcare providers and refining its product-market fit. The involvement of seasoned investors suggests a long-term commitment to scaling these innovations, ensuring that GPx remains at the forefront of the personalized medicine revolution.
See full GPx company page
